Anthropic reaffirmed its AI safety pledge Thursday, November 19, as CEO Dario Amodei addressed investors at the company’s Nasdaq opening bell ceremony. He said the AI developer would prioritize safety and human oversight, even when commercial or political pressures favor faster development.
Amodei’s remarks accompanied Anthropic’s stock market debut following its $83-per-share initial public offering. He emphasized both the potential benefits of artificial intelligence and the risks of deploying increasingly capable systems.
Anthropic AI safety pledge emphasizes human control
Amodei said Anthropic would adjust the pace of AI training and deployment whenever additional safety work was necessary. The commitment includes model testing, alignment research and efforts to understand AI behavior.
He identified misuse by individuals and governments, economic disruption and loss of human control as major concerns.
In a September CBS News interview, Amodei had similarly warned that AI developers must acknowledge the technology’s potential dangers.
TechAmerica.ai previously examined Amodei’s proposal for slower AI development, including independent safety evaluations and cooperation between leading AI companies.
AI development pace remains a divisive industry issue
Amodei’s latest commitment follows his September proposal to establish stronger safeguards for advanced AI systems.
OpenAI CEO Sam Altman, Google DeepMind CEO Demis Hassabis and Elon Musk publicly supported elements of that proposal. However, The Guardian reported that concrete industrywide commitments remained limited.
Anthropic’s approach involves independent evaluators, common safety standards and potential international cooperation. These measures aim to improve oversight as models become more capable.
TechAmerica.ai also covered AI safety discussions involving OpenAI, Anthropic and Google DeepMind.
Nasdaq debut brings Anthropic’s commitments into focus
Anthropic’s IPO priced shares at $83, above its earlier projected range. The offering valued the Claude developer at approximately $1.5 trillion.
The company’s public listing attracted substantial investor attention, with CNBC tracking its Nasdaq debut under the ticker ANT.
During his remarks, Amodei also discussed AI’s potential to accelerate medical research. He recalled losing his father to a disease that became treatable only years later.
He argued that AI could help researchers address scientific problems that currently exceed available human resources.
The commitment now faces a practical test as Anthropic expands its commercial operations. Investors will be watching whether the company maintains its stated safety standards while competing in the fast-growing AI market.










